Xencor Inc

NASDAQ:XNCR   3:59:50 PM EDT
38.84
-0.18 (-0.46%)
Products, Strategic Combinations, Regulatory

Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations

Published: 10/04/2021 11:55 GMT
Xencor Inc (XNCR) - Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and Xmab Cd28 Bispecific Antibody Combinations for the Treatment of Patients With B-cell Malignancies.
Xencor Inc - Second Agreement With Janssen on Bispecific Antibodies Directed Toward Cd28 Co-stimulatory Receptor on T Cells.
Xencor Inc - Xencor to Receive $100 Million Upfront Payment and $25 Million Equity Investment.
Xencor Inc - Eligible for a Mid-teen to Low-twenties Percent Royalty for Plamotamab and Potential Milestone Payments Up to $1.188 Billion.
Xencor Inc - Janssen Will Receive Worldwide Exclusive Development and Commercialization Rights to Plamotamab.
Xencor Inc - Xencor Will Collaborate With Janssen on Further Clinical Development of Plamotamab.
Xencor - Janssen Paying 80% and Xencor Paying 20% of Costs, Including Those for Subcutaneous Formulation Anticipated to Enter Clinical Trials in 2022.